Company intelligence / Profile preview

BreakBio Corp.

Miami, Florida, United Statesbreakbio.com ↗

Ownership: Private
Development stage: Other

Overview

BreakBio has received FDA IND approval for its lead program, BreakVax, a personalized peptide immunotherapy designed using proprietary AI/ML and mass spectrometry. The first clinical trial will target metastatic colorectal cancer, with the goal of expanding to all solid tumors. The company aims to achieve FDA breakthrough designation as it advances through early-stage human trials[3].

Therapeutic areas: Oncology
Modalities: Personalized peptide vaccinesPeptide immunotherapySynthetic protein-based therapeutics[1][3]
Industry: Biotech

Drug pipeline

1 asset

BreakVax

Partnerships

Collaborations with leading academic oncologists at USC Norris Comprehensive Cancer Center, NCT Heidelberg, Weill Cornell Cancer Center (consultants/advisors)[2]

Beyond the preview

Go deeper on BreakBio Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BreakBio Corp..

Explore the full profile